Nanosonics Ltd receives US approval for trophon2

Nanosonics Ltd (ASX:NAN) has received the important clearance for trophon2.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nanosonics Ltd (ASX: NAN) has announced this morning that it has received US Food and Drug Administration clearance for its new device, trophon2.

Nanosonics describes itself as a leader in infection control solutions. It has received the vitally-important FDA 510(k) clearance for its second generation trophon device, trophon2.

The Chief Executive Officer and President of Nanosonics, Michael Kavanagh, said "This is excellent news delivering earlier than anticipated FDA clearance for our next generation trophon device. Further, it delivers the first regulatory approval of our targeted new infection prevention solutions."

The company has put a lot of energy into re-designing the trophon device to make it even better than the last one. It has new mechanical and software design that apparently gives a range of new benefits based on input and feedback from its global customer base.

Nansonics took the views of infection prevention specialists into account on the future trends and requirements of infection control devices. The new device has a redesigned chamber for new and existing probes as well as a number of other features.

The new device has also been designed with the European market in mind, as each country may have specific guidelines for infection control devices. The regulatory submission for Europe is currently under review.

Mr Kavanagh said that the commercial release for trophon2 is anticipated for the first quarter of the 2019 financial year. The product is currently being put into the manufacturing cycle with a ramp up of production expected during the next three months.

Nanosonics also said that the original trophon device will remain in the market as an entry level device, although the company expects most sales will shift to the new device.

The company did warn that there could be a short-term impact on both inventory and trading volumes as the change occurs, which will have a 'transitionary impact' on revenue recognition in the current quarter. However, any short-term negative impact is expected to be overcome after the full commercial release of trophon2.

Foolish takeaway

Getting approval sooner than expected should be a good thing for the company and will hopefully lead to continued long-term growth for Nanosonics. At the current value it could be a decent long-term buy as the share price has dropped off over the last few months. However, I'm personally not going to invest in the near future until at least the transition phase is over.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »